Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 185Neoplasms 11Prostate Adenocarcinoma 3Neoplasm Metastasis 3Adenocarcinoma 2Urogenital Neoplasms 1Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunction, Physiological 1Recurrence 1Prostatic Diseases 1Primary Dysautonomias 1PSA Level Greater Than Two 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasms, Glandular and Epithelial 1Lymphatic Metastasis 1Lower Urinary Tract Symptoms 1Kidney Diseases 1Hypertension 1Hormone Sensitive Prostate Cancer 1Genital Neoplasms, Male 1Castration-resistant Prostate Cancer Patients with Oligometastases 1Carcinoma 1Advanced Prostate Cancer 1Advanced Prostate Adenocarcinoma 1

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Nivolumab 1Leuprolide 1Goserelin 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hormone Sensitive Prostate Cancer × Leuprolide × Genitourinary × Clear all
NCT04126070 2026-05-27

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
47 enrolled 16 charts
Genitourinary

Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡